We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Diatron MI Plc

Develops, manufactures and markets hematology analyzers, clinical chemistry analyzers, and associated reagents for hu... read more Featured Products: More products

Download Mobile App




New Version of 3-Part Differential Hematology Analyzer Launched

By LabMedica International staff writers
Posted on 08 Apr 2014
Print article
Image: The Abacus 3CT hematology analyzer, a compact, bench-top, flexible 3-part differential analyzer (Photo courtesy of the Diatron Group).
Image: The Abacus 3CT hematology analyzer, a compact, bench-top, flexible 3-part differential analyzer (Photo courtesy of the Diatron Group).
A new hematology analyzer is particularly suitable for small laboratories, satellite clinics, and doctors’ offices.

Launched by the Diatron Group (Budapest, Hungary) the new Abacus 3CT hematology analyzer is a compact, bench-top, flexible 3-part differential analyzer. It offers 22 parameters thus delivering more patient data, and has a cap piercing capability that enables it to be used with sample tubes that are open or closed.

The new analyzer has been enhanced significantly from the original version. The most visually apparent changes are the introduction of the latest 8” high resolution and the color touch screen with new intuitive multilingual user interface, which makes it clear and simple to operate.

The new Abacus 3CT has an enhanced package of on-board quality control (QC) features. The QC capacity has been greatly increased to 24 lots, and QC values can now be loaded via QR codes or USB to avoid any incorrect assignment of values. Operating rights can also be assigned to selected operators to ensure that only trained persons can use the system. In addition, an on-board log details when reagents were last changed, with a constant on-screen display of reagent expiry dates as well as remaining reagent volumes. Other QC features include aperture anticlog protection and automatic cleaning after every 15 sample measurements.

To accommodate the increased volume of data generated by the 22 parameter measurements, the on-board data storage capacity of the Abacus 3CT has been doubled to 10,000 records, with improved laboratory information system (LIS) connectivity for results transfer.

Diatron develops, manufactures, and markets hematology and clinical chemistry analyzers, and associated reagents for human medical and veterinary use. An R&D/engineering team develops and manufactures a broad product range of products including: hematology analyzers, hematology reagents (both for its own and other manufacturers’ analyzers), hematology control material, clinical chemistry analyzers, clinical chemistry reagents, and clinical chemistry controls.

Related Links:

Diatron Group


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.